As AD shares many pathological characteristics with type 2 diabetes mellitus and is also characterized with impairments in circadian rhythm, harnessing of GLP-1 for its neuroprotective effects has been a recent focus, particularly with the repurposing of a type II diabetes drug and GLP-1 analogue, exendin-4. The gene discussed is GCG; the disease is Alzheimer disease.